Blog

DEEP RESEARCH · CUREVERSE

Cureverse: A KIST-Origin Drug Developer Built Around CV-01 and CV-02

A biotech deeptech analysis of the CV-01 Alzheimer’s licensing deal, CV-02 multiple sclerosis program, and 2027 IPO path

Published: 2025-09-12 · Private biotech/drug-development analysis · Naver Blog

Investment decisions are your own responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

I reviewed Cureverse while pre-researching companies that recently won deeptech awards. The key points are its origin as a KIST-based research company, an approximately KRW 500 billion licensing deal for CV-01, a KRW 25 billion Series B, U.S. FDA IND clearance for a Phase 1 trial of CV-02, and a stated 2027 IPO target. Like any biotech, however, the company’s value depends heavily on the clinical success of CV-01 and CV-02.

Cureverse’s two-pillar portfolioA mix of high-risk innovation and improved validated biology
KIST originBio-Star and research-company model
CV-01Alzheimer’s, non-amyloid/neuroinflammation
CV-02Multiple sclerosis, S1P1 selectivity
CapitalLicensing, Series B, IPO target
An early biotech structure combining science, commercialization leadership, and financing

1. Company structure: a KIST-origin research company

Official fact: The source states that Cureverse was founded in October 2021 as a research company based on Korea Institute of Science and Technology technology. Its headquarters are on the KIST campus, and the model links seed technology with experienced biotech entrepreneurs through KIST’s Bio-Star program.

Interpretation: Cureverse’s strength is that academic technology and commercialization experience are not separated. KIST seed technology, CEO Sung-Jin Cho’s development/regulatory/business experience, Ki-Duck Park’s original science, and CSO Jung-Wook Jin’s follow-on pipeline work complement one another.

CEO

Sung-Jin Cho

Leads industrialization and commercialization, including development, regulatory strategy, financing, and deal-making.

Science

Ki-Duck Park

Head of KIST’s Brain Science Institute and original inventor behind CV-01 and CV-02 technologies.

Pipeline

Jung-Wook Jin

CSO responsible for discovering follow-on pipeline assets.

2. CV-01: a non-amyloid Alzheimer’s approach

Official fact: The source describes CV-01 as the core Alzheimer’s candidate and says it received external validation through an approximately KRW 500 billion licensing agreement. CV-01 is framed as a non-amyloid asset focused on neuroinflammation modulation, unlike conventional amyloid-centered approaches.

AssetIndicationStrategyMeaning
CV-01Alzheimer’s diseaseNon-amyloid, neuroinflammation modulationLarge licensing deal externally validates the approach
CV-02Multiple sclerosisSelective S1P1 small moleculeBest-in-class strategy to improve safety around a validated target

Interpretation: CV-01 is the high-risk, high-upside asset that opens the company’s valuation ceiling. The licensing deal is positive, but Alzheimer’s trials have high failure rates, so the next clinical data matter most.

3. CV-02: pursuing better safety in multiple sclerosis

Official fact: The source states that CV-02 is a small molecule selectively targeting S1P1R and is intended as a best-in-class improvement over existing S1P1 drugs by reducing or eliminating cardiovascular side effects. In June 2025, Cureverse received U.S. FDA IND clearance for a Phase 1 trial of CV-02, planned in 64 healthy adults to evaluate safety, tolerability, and pharmacokinetics.

The source estimates the global multiple sclerosis drug market at more than $21 billion in 2023 and expects it to grow to $33-39 billion by 2030-2032.

CV-02 development logicImprove the side-effect profile around a validated target
Validated targetS1P1R
ProblemCardiovascular side effects
CV-02Selectivity and improved safety
Clinical pathU.S. FDA Phase 1 IND
A second pillar that reduces dependence on CV-01 alone

4. Financing and IPO path

Official fact: The source explains that the KRW 25 billion Series B raised after the CV-01 licensing deal provides capital to move the core pipeline toward key clinical inflection points. The company targets an IPO in 2027, assuming successful clinical execution.

  • Strengths: KIST-origin technology, large licensing deal, and two balanced core pipeline assets.
  • Opportunity: Alzheimer’s disease and multiple sclerosis are both large unmet-need markets.
  • Risks: clinical failure, cash burn, dependence on core assets, and IPO market conditions.
  • Checkpoints: CV-01 follow-on development, CV-02 Phase 1 safety data, and additional licensing or co-development deals.

5. Final view

Interpretation: Cureverse has a better structure than a biotech built around only one candidate. Still, actual clinical data matter more than the headline licensing amount. I would focus on CV-01’s next development stage, CV-02 safety validation, and the cash runway before the planned 2027 IPO.

Sources

Naver original